Algal Research-Biomass Biofuels and Bioproducts-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2153262, encodeId=b7c021532624e, content=偏重的研究方向：脂质代谢 经验分享：2023.8.17Submitted to Journal mark一下，后续有通知会更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55858640267, createdName=ms7000000743266002, createdTime=Thu Aug 17 16:47:54 CST 2023, time=2023-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1105400, encodeId=1af211054002f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105399, encodeId=b03f1105399ed, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849121, encodeId=357484912121, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2017年09月17号投稿，11.18号收到大修意见。12月28号修改后提交，1月8号接收。速度还可以接受，编辑处理效率很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92c5414061, createdName=ms5413142457057855, createdTime=Tue Jan 08 15:12:19 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846613, encodeId=eec4846613a9, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿周期2个月，每步动态都有邮件提示。 一审(送审2个月)后，编辑发邮件说需要再寻求其他审稿人意见，此时状态又变为under review. 以为编辑要再找审稿人重新审，但是第二天就被拒稿了。 看了下审稿意见：两个审稿人说修改后接受，第三个给的评价不是很好，但没说拒稿。没搞懂编辑的逻辑。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Sat Aug 25 01:18:33 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840602, encodeId=9be584060214, content=7.25 投递 8.4 送交编辑 10.9 一审结束，两个审稿人一个大修，一个拒稿，编辑给大修 11.27 大修后返给编辑，编辑送交交新审稿人二审 01.08 二审结束，意见：外送润色 01.17 外送润色后返回编辑 01.19 编辑，意见小修、 01.22 接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Mon Jan 22 21:07:38 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838935, encodeId=2b338389356a, content=小修之后编辑又让改了格式，已经接收！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c235413991, createdName=ms2848770090237977, createdTime=Thu Oct 26 19:12:55 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838632, encodeId=197083863246, content=小修，在修改中，但是感觉自引率高的有点吓人啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae65413999, createdName=ms4600315023772712, createdTime=Sat Oct 07 19:01:31 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836299, encodeId=d892836299c3, content=我想问一下，如果文章初次没有接收，编辑给发的邮件主题是什么 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93af5414037, createdName=ms5106277377443647, createdTime=Fri Apr 21 01:46:24 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832007, encodeId=994a83200ede, content=审稿速度:4.0 经验分享：这个期刊在藻方向很好的。投了两篇均接收。一篇是藻培养，一篇藻回收。最主要还是看文章有无科学性，研究内容不一定非要新颖，但是要有原创性。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5b85413973, createdName=ms7405767186922736, createdTime=Tue Apr 19 21:58:44 CST 2016, time=2016-04-19, status=1, ipAttribution=)]

2023-08-17 ms7000000743266002 来自北京

偏重的研究方向：脂质代谢
经验分享：2023.8.17Submitted to Journal
mark一下，后续有通知会更新

137 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2153262, encodeId=b7c021532624e, content=偏重的研究方向：脂质代谢 经验分享：2023.8.17Submitted to Journal mark一下，后续有通知会更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55858640267, createdName=ms7000000743266002, createdTime=Thu Aug 17 16:47:54 CST 2023, time=2023-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1105400, encodeId=1af211054002f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105399, encodeId=b03f1105399ed, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849121, encodeId=357484912121, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2017年09月17号投稿，11.18号收到大修意见。12月28号修改后提交，1月8号接收。速度还可以接受，编辑处理效率很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92c5414061, createdName=ms5413142457057855, createdTime=Tue Jan 08 15:12:19 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846613, encodeId=eec4846613a9, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿周期2个月，每步动态都有邮件提示。 一审(送审2个月)后，编辑发邮件说需要再寻求其他审稿人意见，此时状态又变为under review. 以为编辑要再找审稿人重新审，但是第二天就被拒稿了。 看了下审稿意见：两个审稿人说修改后接受，第三个给的评价不是很好，但没说拒稿。没搞懂编辑的逻辑。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Sat Aug 25 01:18:33 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840602, encodeId=9be584060214, content=7.25 投递 8.4 送交编辑 10.9 一审结束，两个审稿人一个大修，一个拒稿，编辑给大修 11.27 大修后返给编辑，编辑送交交新审稿人二审 01.08 二审结束，意见：外送润色 01.17 外送润色后返回编辑 01.19 编辑，意见小修、 01.22 接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Mon Jan 22 21:07:38 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838935, encodeId=2b338389356a, content=小修之后编辑又让改了格式，已经接收！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c235413991, createdName=ms2848770090237977, createdTime=Thu Oct 26 19:12:55 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838632, encodeId=197083863246, content=小修，在修改中，但是感觉自引率高的有点吓人啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae65413999, createdName=ms4600315023772712, createdTime=Sat Oct 07 19:01:31 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836299, encodeId=d892836299c3, content=我想问一下，如果文章初次没有接收，编辑给发的邮件主题是什么 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93af5414037, createdName=ms5106277377443647, createdTime=Fri Apr 21 01:46:24 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832007, encodeId=994a83200ede, content=审稿速度:4.0 经验分享：这个期刊在藻方向很好的。投了两篇均接收。一篇是藻培养，一篇藻回收。最主要还是看文章有无科学性，研究内容不一定非要新颖，但是要有原创性。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5b85413973, createdName=ms7405767186922736, createdTime=Tue Apr 19 21:58:44 CST 2016, time=2016-04-19, status=1, ipAttribution=)]

2021-12-27 msSSSSSD

如果文章发表了未提供ORCIDID如何添加？

42 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2153262, encodeId=b7c021532624e, content=偏重的研究方向：脂质代谢 经验分享：2023.8.17Submitted to Journal mark一下，后续有通知会更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55858640267, createdName=ms7000000743266002, createdTime=Thu Aug 17 16:47:54 CST 2023, time=2023-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1105400, encodeId=1af211054002f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105399, encodeId=b03f1105399ed, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849121, encodeId=357484912121, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2017年09月17号投稿，11.18号收到大修意见。12月28号修改后提交，1月8号接收。速度还可以接受，编辑处理效率很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92c5414061, createdName=ms5413142457057855, createdTime=Tue Jan 08 15:12:19 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846613, encodeId=eec4846613a9, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿周期2个月，每步动态都有邮件提示。 一审(送审2个月)后，编辑发邮件说需要再寻求其他审稿人意见，此时状态又变为under review. 以为编辑要再找审稿人重新审，但是第二天就被拒稿了。 看了下审稿意见：两个审稿人说修改后接受，第三个给的评价不是很好，但没说拒稿。没搞懂编辑的逻辑。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Sat Aug 25 01:18:33 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840602, encodeId=9be584060214, content=7.25 投递 8.4 送交编辑 10.9 一审结束，两个审稿人一个大修，一个拒稿，编辑给大修 11.27 大修后返给编辑，编辑送交交新审稿人二审 01.08 二审结束，意见：外送润色 01.17 外送润色后返回编辑 01.19 编辑，意见小修、 01.22 接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Mon Jan 22 21:07:38 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838935, encodeId=2b338389356a, content=小修之后编辑又让改了格式，已经接收！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c235413991, createdName=ms2848770090237977, createdTime=Thu Oct 26 19:12:55 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838632, encodeId=197083863246, content=小修，在修改中，但是感觉自引率高的有点吓人啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae65413999, createdName=ms4600315023772712, createdTime=Sat Oct 07 19:01:31 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836299, encodeId=d892836299c3, content=我想问一下，如果文章初次没有接收，编辑给发的邮件主题是什么 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93af5414037, createdName=ms5106277377443647, createdTime=Fri Apr 21 01:46:24 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832007, encodeId=994a83200ede, content=审稿速度:4.0 经验分享：这个期刊在藻方向很好的。投了两篇均接收。一篇是藻培养，一篇藻回收。最主要还是看文章有无科学性，研究内容不一定非要新颖，但是要有原创性。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5b85413973, createdName=ms7405767186922736, createdTime=Tue Apr 19 21:58:44 CST 2016, time=2016-04-19, status=1, ipAttribution=)]

2021-12-27 小动量

如何判断两种药物之间是协同作用还是相加作用？

47 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2153262, encodeId=b7c021532624e, content=偏重的研究方向：脂质代谢 经验分享：2023.8.17Submitted to Journal mark一下，后续有通知会更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55858640267, createdName=ms7000000743266002, createdTime=Thu Aug 17 16:47:54 CST 2023, time=2023-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1105400, encodeId=1af211054002f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105399, encodeId=b03f1105399ed, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849121, encodeId=357484912121, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2017年09月17号投稿，11.18号收到大修意见。12月28号修改后提交，1月8号接收。速度还可以接受，编辑处理效率很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92c5414061, createdName=ms5413142457057855, createdTime=Tue Jan 08 15:12:19 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846613, encodeId=eec4846613a9, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿周期2个月，每步动态都有邮件提示。 一审(送审2个月)后，编辑发邮件说需要再寻求其他审稿人意见，此时状态又变为under review. 以为编辑要再找审稿人重新审，但是第二天就被拒稿了。 看了下审稿意见：两个审稿人说修改后接受，第三个给的评价不是很好，但没说拒稿。没搞懂编辑的逻辑。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Sat Aug 25 01:18:33 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840602, encodeId=9be584060214, content=7.25 投递 8.4 送交编辑 10.9 一审结束，两个审稿人一个大修，一个拒稿，编辑给大修 11.27 大修后返给编辑，编辑送交交新审稿人二审 01.08 二审结束，意见：外送润色 01.17 外送润色后返回编辑 01.19 编辑，意见小修、 01.22 接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Mon Jan 22 21:07:38 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838935, encodeId=2b338389356a, content=小修之后编辑又让改了格式，已经接收！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c235413991, createdName=ms2848770090237977, createdTime=Thu Oct 26 19:12:55 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838632, encodeId=197083863246, content=小修，在修改中，但是感觉自引率高的有点吓人啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae65413999, createdName=ms4600315023772712, createdTime=Sat Oct 07 19:01:31 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836299, encodeId=d892836299c3, content=我想问一下，如果文章初次没有接收，编辑给发的邮件主题是什么 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93af5414037, createdName=ms5106277377443647, createdTime=Fri Apr 21 01:46:24 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832007, encodeId=994a83200ede, content=审稿速度:4.0 经验分享：这个期刊在藻方向很好的。投了两篇均接收。一篇是藻培养，一篇藻回收。最主要还是看文章有无科学性，研究内容不一定非要新颖，但是要有原创性。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5b85413973, createdName=ms7405767186922736, createdTime=Tue Apr 19 21:58:44 CST 2016, time=2016-04-19, status=1, ipAttribution=)]

2019-01-08 ms5413142457057855

审稿速度:1.0 | 投稿命中率:75.0
经验分享：2017年09月17号投稿，11.18号收到大修意见。12月28号修改后提交，1月8号接收。速度还可以接受，编辑处理效率很高。

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2153262, encodeId=b7c021532624e, content=偏重的研究方向：脂质代谢 经验分享：2023.8.17Submitted to Journal mark一下，后续有通知会更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55858640267, createdName=ms7000000743266002, createdTime=Thu Aug 17 16:47:54 CST 2023, time=2023-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1105400, encodeId=1af211054002f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105399, encodeId=b03f1105399ed, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849121, encodeId=357484912121, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2017年09月17号投稿，11.18号收到大修意见。12月28号修改后提交，1月8号接收。速度还可以接受，编辑处理效率很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92c5414061, createdName=ms5413142457057855, createdTime=Tue Jan 08 15:12:19 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846613, encodeId=eec4846613a9, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿周期2个月，每步动态都有邮件提示。 一审(送审2个月)后，编辑发邮件说需要再寻求其他审稿人意见，此时状态又变为under review. 以为编辑要再找审稿人重新审，但是第二天就被拒稿了。 看了下审稿意见：两个审稿人说修改后接受，第三个给的评价不是很好，但没说拒稿。没搞懂编辑的逻辑。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Sat Aug 25 01:18:33 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840602, encodeId=9be584060214, content=7.25 投递 8.4 送交编辑 10.9 一审结束，两个审稿人一个大修，一个拒稿，编辑给大修 11.27 大修后返给编辑，编辑送交交新审稿人二审 01.08 二审结束，意见：外送润色 01.17 外送润色后返回编辑 01.19 编辑，意见小修、 01.22 接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Mon Jan 22 21:07:38 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838935, encodeId=2b338389356a, content=小修之后编辑又让改了格式，已经接收！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c235413991, createdName=ms2848770090237977, createdTime=Thu Oct 26 19:12:55 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838632, encodeId=197083863246, content=小修，在修改中，但是感觉自引率高的有点吓人啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae65413999, createdName=ms4600315023772712, createdTime=Sat Oct 07 19:01:31 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836299, encodeId=d892836299c3, content=我想问一下，如果文章初次没有接收，编辑给发的邮件主题是什么 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93af5414037, createdName=ms5106277377443647, createdTime=Fri Apr 21 01:46:24 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832007, encodeId=994a83200ede, content=审稿速度:4.0 经验分享：这个期刊在藻方向很好的。投了两篇均接收。一篇是藻培养，一篇藻回收。最主要还是看文章有无科学性，研究内容不一定非要新颖，但是要有原创性。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5b85413973, createdName=ms7405767186922736, createdTime=Tue Apr 19 21:58:44 CST 2016, time=2016-04-19, status=1, ipAttribution=)]

2018-08-25 ms4355985535640256

审稿速度:3.0 | 投稿命中率:75.0
经验分享：审稿周期2个月，每步动态都有邮件提示。
一审(送审2个月)后，编辑发邮件说需要再寻求其他审稿人意见，此时状态又变为under review.
以为编辑要再找审稿人重新审，但是第二天就被拒稿了。
看了下审稿意见：两个审稿人说修改后接受，第三个给的评价不是很好，但没说拒稿。没搞懂编辑的逻辑。

96 0

[GetPortalCommentsPageByObjectIdResponse(id=2153262, encodeId=b7c021532624e, content=偏重的研究方向：脂质代谢 经验分享：2023.8.17Submitted to Journal mark一下，后续有通知会更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55858640267, createdName=ms7000000743266002, createdTime=Thu Aug 17 16:47:54 CST 2023, time=2023-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1105400, encodeId=1af211054002f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105399, encodeId=b03f1105399ed, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849121, encodeId=357484912121, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2017年09月17号投稿，11.18号收到大修意见。12月28号修改后提交，1月8号接收。速度还可以接受，编辑处理效率很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92c5414061, createdName=ms5413142457057855, createdTime=Tue Jan 08 15:12:19 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846613, encodeId=eec4846613a9, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿周期2个月，每步动态都有邮件提示。 一审(送审2个月)后，编辑发邮件说需要再寻求其他审稿人意见，此时状态又变为under review. 以为编辑要再找审稿人重新审，但是第二天就被拒稿了。 看了下审稿意见：两个审稿人说修改后接受，第三个给的评价不是很好，但没说拒稿。没搞懂编辑的逻辑。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Sat Aug 25 01:18:33 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840602, encodeId=9be584060214, content=7.25 投递 8.4 送交编辑 10.9 一审结束，两个审稿人一个大修，一个拒稿，编辑给大修 11.27 大修后返给编辑，编辑送交交新审稿人二审 01.08 二审结束，意见：外送润色 01.17 外送润色后返回编辑 01.19 编辑，意见小修、 01.22 接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Mon Jan 22 21:07:38 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838935, encodeId=2b338389356a, content=小修之后编辑又让改了格式，已经接收！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c235413991, createdName=ms2848770090237977, createdTime=Thu Oct 26 19:12:55 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838632, encodeId=197083863246, content=小修，在修改中，但是感觉自引率高的有点吓人啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae65413999, createdName=ms4600315023772712, createdTime=Sat Oct 07 19:01:31 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836299, encodeId=d892836299c3, content=我想问一下，如果文章初次没有接收，编辑给发的邮件主题是什么 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93af5414037, createdName=ms5106277377443647, createdTime=Fri Apr 21 01:46:24 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832007, encodeId=994a83200ede, content=审稿速度:4.0 经验分享：这个期刊在藻方向很好的。投了两篇均接收。一篇是藻培养，一篇藻回收。最主要还是看文章有无科学性，研究内容不一定非要新颖，但是要有原创性。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5b85413973, createdName=ms7405767186922736, createdTime=Tue Apr 19 21:58:44 CST 2016, time=2016-04-19, status=1, ipAttribution=)]

2018-01-22 ms4355985535640256

7.25 投递
8.4 送交编辑
10.9 一审结束，两个审稿人一个大修，一个拒稿，编辑给大修
11.27 大修后返给编辑，编辑送交交新审稿人二审
01.08 二审结束，意见：外送润色
01.17 外送润色后返回编辑
01.19 编辑，意见小修、
01.22 接受

100 0

[GetPortalCommentsPageByObjectIdResponse(id=2153262, encodeId=b7c021532624e, content=偏重的研究方向：脂质代谢 经验分享：2023.8.17Submitted to Journal mark一下，后续有通知会更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55858640267, createdName=ms7000000743266002, createdTime=Thu Aug 17 16:47:54 CST 2023, time=2023-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1105400, encodeId=1af211054002f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105399, encodeId=b03f1105399ed, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849121, encodeId=357484912121, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2017年09月17号投稿，11.18号收到大修意见。12月28号修改后提交，1月8号接收。速度还可以接受，编辑处理效率很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92c5414061, createdName=ms5413142457057855, createdTime=Tue Jan 08 15:12:19 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846613, encodeId=eec4846613a9, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿周期2个月，每步动态都有邮件提示。 一审(送审2个月)后，编辑发邮件说需要再寻求其他审稿人意见，此时状态又变为under review. 以为编辑要再找审稿人重新审，但是第二天就被拒稿了。 看了下审稿意见：两个审稿人说修改后接受，第三个给的评价不是很好，但没说拒稿。没搞懂编辑的逻辑。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Sat Aug 25 01:18:33 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840602, encodeId=9be584060214, content=7.25 投递 8.4 送交编辑 10.9 一审结束，两个审稿人一个大修，一个拒稿，编辑给大修 11.27 大修后返给编辑，编辑送交交新审稿人二审 01.08 二审结束，意见：外送润色 01.17 外送润色后返回编辑 01.19 编辑，意见小修、 01.22 接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Mon Jan 22 21:07:38 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838935, encodeId=2b338389356a, content=小修之后编辑又让改了格式，已经接收！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c235413991, createdName=ms2848770090237977, createdTime=Thu Oct 26 19:12:55 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838632, encodeId=197083863246, content=小修，在修改中，但是感觉自引率高的有点吓人啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae65413999, createdName=ms4600315023772712, createdTime=Sat Oct 07 19:01:31 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836299, encodeId=d892836299c3, content=我想问一下，如果文章初次没有接收，编辑给发的邮件主题是什么 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93af5414037, createdName=ms5106277377443647, createdTime=Fri Apr 21 01:46:24 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832007, encodeId=994a83200ede, content=审稿速度:4.0 经验分享：这个期刊在藻方向很好的。投了两篇均接收。一篇是藻培养，一篇藻回收。最主要还是看文章有无科学性，研究内容不一定非要新颖，但是要有原创性。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5b85413973, createdName=ms7405767186922736, createdTime=Tue Apr 19 21:58:44 CST 2016, time=2016-04-19, status=1, ipAttribution=)]

2017-10-26 ms2848770090237977

小修之后编辑又让改了格式，已经接收！

86 0

[GetPortalCommentsPageByObjectIdResponse(id=2153262, encodeId=b7c021532624e, content=偏重的研究方向：脂质代谢 经验分享：2023.8.17Submitted to Journal mark一下，后续有通知会更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55858640267, createdName=ms7000000743266002, createdTime=Thu Aug 17 16:47:54 CST 2023, time=2023-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1105400, encodeId=1af211054002f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105399, encodeId=b03f1105399ed, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849121, encodeId=357484912121, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2017年09月17号投稿，11.18号收到大修意见。12月28号修改后提交，1月8号接收。速度还可以接受，编辑处理效率很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92c5414061, createdName=ms5413142457057855, createdTime=Tue Jan 08 15:12:19 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846613, encodeId=eec4846613a9, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿周期2个月，每步动态都有邮件提示。 一审(送审2个月)后，编辑发邮件说需要再寻求其他审稿人意见，此时状态又变为under review. 以为编辑要再找审稿人重新审，但是第二天就被拒稿了。 看了下审稿意见：两个审稿人说修改后接受，第三个给的评价不是很好，但没说拒稿。没搞懂编辑的逻辑。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Sat Aug 25 01:18:33 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840602, encodeId=9be584060214, content=7.25 投递 8.4 送交编辑 10.9 一审结束，两个审稿人一个大修，一个拒稿，编辑给大修 11.27 大修后返给编辑，编辑送交交新审稿人二审 01.08 二审结束，意见：外送润色 01.17 外送润色后返回编辑 01.19 编辑，意见小修、 01.22 接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Mon Jan 22 21:07:38 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838935, encodeId=2b338389356a, content=小修之后编辑又让改了格式，已经接收！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c235413991, createdName=ms2848770090237977, createdTime=Thu Oct 26 19:12:55 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838632, encodeId=197083863246, content=小修，在修改中，但是感觉自引率高的有点吓人啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae65413999, createdName=ms4600315023772712, createdTime=Sat Oct 07 19:01:31 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836299, encodeId=d892836299c3, content=我想问一下，如果文章初次没有接收，编辑给发的邮件主题是什么 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93af5414037, createdName=ms5106277377443647, createdTime=Fri Apr 21 01:46:24 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832007, encodeId=994a83200ede, content=审稿速度:4.0 经验分享：这个期刊在藻方向很好的。投了两篇均接收。一篇是藻培养，一篇藻回收。最主要还是看文章有无科学性，研究内容不一定非要新颖，但是要有原创性。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5b85413973, createdName=ms7405767186922736, createdTime=Tue Apr 19 21:58:44 CST 2016, time=2016-04-19, status=1, ipAttribution=)]

2017-10-07 ms4600315023772712

小修，在修改中，但是感觉自引率高的有点吓人啊

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2153262, encodeId=b7c021532624e, content=偏重的研究方向：脂质代谢 经验分享：2023.8.17Submitted to Journal mark一下，后续有通知会更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55858640267, createdName=ms7000000743266002, createdTime=Thu Aug 17 16:47:54 CST 2023, time=2023-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1105400, encodeId=1af211054002f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105399, encodeId=b03f1105399ed, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849121, encodeId=357484912121, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2017年09月17号投稿，11.18号收到大修意见。12月28号修改后提交，1月8号接收。速度还可以接受，编辑处理效率很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92c5414061, createdName=ms5413142457057855, createdTime=Tue Jan 08 15:12:19 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846613, encodeId=eec4846613a9, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿周期2个月，每步动态都有邮件提示。 一审(送审2个月)后，编辑发邮件说需要再寻求其他审稿人意见，此时状态又变为under review. 以为编辑要再找审稿人重新审，但是第二天就被拒稿了。 看了下审稿意见：两个审稿人说修改后接受，第三个给的评价不是很好，但没说拒稿。没搞懂编辑的逻辑。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Sat Aug 25 01:18:33 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840602, encodeId=9be584060214, content=7.25 投递 8.4 送交编辑 10.9 一审结束，两个审稿人一个大修，一个拒稿，编辑给大修 11.27 大修后返给编辑，编辑送交交新审稿人二审 01.08 二审结束，意见：外送润色 01.17 外送润色后返回编辑 01.19 编辑，意见小修、 01.22 接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Mon Jan 22 21:07:38 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838935, encodeId=2b338389356a, content=小修之后编辑又让改了格式，已经接收！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c235413991, createdName=ms2848770090237977, createdTime=Thu Oct 26 19:12:55 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838632, encodeId=197083863246, content=小修，在修改中，但是感觉自引率高的有点吓人啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae65413999, createdName=ms4600315023772712, createdTime=Sat Oct 07 19:01:31 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836299, encodeId=d892836299c3, content=我想问一下，如果文章初次没有接收，编辑给发的邮件主题是什么 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93af5414037, createdName=ms5106277377443647, createdTime=Fri Apr 21 01:46:24 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832007, encodeId=994a83200ede, content=审稿速度:4.0 经验分享：这个期刊在藻方向很好的。投了两篇均接收。一篇是藻培养，一篇藻回收。最主要还是看文章有无科学性，研究内容不一定非要新颖，但是要有原创性。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5b85413973, createdName=ms7405767186922736, createdTime=Tue Apr 19 21:58:44 CST 2016, time=2016-04-19, status=1, ipAttribution=)]

2017-04-21 ms5106277377443647

我想问一下，如果文章初次没有接收，编辑给发的邮件主题是什么

93 0

[GetPortalCommentsPageByObjectIdResponse(id=2153262, encodeId=b7c021532624e, content=偏重的研究方向：脂质代谢 经验分享：2023.8.17Submitted to Journal mark一下，后续有通知会更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55858640267, createdName=ms7000000743266002, createdTime=Thu Aug 17 16:47:54 CST 2023, time=2023-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1105400, encodeId=1af211054002f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105399, encodeId=b03f1105399ed, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849121, encodeId=357484912121, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2017年09月17号投稿，11.18号收到大修意见。12月28号修改后提交，1月8号接收。速度还可以接受，编辑处理效率很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92c5414061, createdName=ms5413142457057855, createdTime=Tue Jan 08 15:12:19 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846613, encodeId=eec4846613a9, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿周期2个月，每步动态都有邮件提示。 一审(送审2个月)后，编辑发邮件说需要再寻求其他审稿人意见，此时状态又变为under review. 以为编辑要再找审稿人重新审，但是第二天就被拒稿了。 看了下审稿意见：两个审稿人说修改后接受，第三个给的评价不是很好，但没说拒稿。没搞懂编辑的逻辑。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Sat Aug 25 01:18:33 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840602, encodeId=9be584060214, content=7.25 投递 8.4 送交编辑 10.9 一审结束，两个审稿人一个大修，一个拒稿，编辑给大修 11.27 大修后返给编辑，编辑送交交新审稿人二审 01.08 二审结束，意见：外送润色 01.17 外送润色后返回编辑 01.19 编辑，意见小修、 01.22 接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab8c5414018, createdName=ms4355985535640256, createdTime=Mon Jan 22 21:07:38 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838935, encodeId=2b338389356a, content=小修之后编辑又让改了格式，已经接收！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c235413991, createdName=ms2848770090237977, createdTime=Thu Oct 26 19:12:55 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=838632, encodeId=197083863246, content=小修，在修改中，但是感觉自引率高的有点吓人啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae65413999, createdName=ms4600315023772712, createdTime=Sat Oct 07 19:01:31 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836299, encodeId=d892836299c3, content=我想问一下，如果文章初次没有接收，编辑给发的邮件主题是什么 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93af5414037, createdName=ms5106277377443647, createdTime=Fri Apr 21 01:46:24 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832007, encodeId=994a83200ede, content=审稿速度:4.0 经验分享：这个期刊在藻方向很好的。投了两篇均接收。一篇是藻培养，一篇藻回收。最主要还是看文章有无科学性，研究内容不一定非要新颖，但是要有原创性。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5b85413973, createdName=ms7405767186922736, createdTime=Tue Apr 19 21:58:44 CST 2016, time=2016-04-19, status=1, ipAttribution=)]

2016-04-19 ms7405767186922736

审稿速度:4.0
经验分享：这个期刊在藻方向很好的。投了两篇均接收。一篇是藻培养，一篇藻回收。最主要还是看文章有无科学性，研究内容不一定非要新颖，但是要有原创性。

110 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务